Novartis Venture Fund returned to reinvest in inflammatory disease drug developer Inflazome as part of its $45.6m series B round.
The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.
Novartis and Access Industries unit Clal Biotechnology Industries both took part in the neurological disorder drug developer's series B round.
Busy Burr has moved on from her position as head of corporate venturing unit Humana Health Ventures as Humana reorganises its VC stakes.
Vrije Universiteit Brussel’s Camel-IDS collected funding from investors including Novo for a radiation-based oncology platform that will initially target Her2-positive brain metastatic breast cancer.
Merck Group's M Ventures unit led the RNA therapy startup's series A round, which featured Amgen, Illumina, AbbVie and Mitsubishi Tanabe Pharma.
Strategic partner Eli Lilly invested $15m while Pfizer, Ping An Ventures and Taiho Ventures also contributed to the immunotherapy developer's series B round.
Pfizer Ventures and 6 Dimensions Capital joined Merck & Co, Sanofi, Eli Lilly and Amgen in Kymera's series B round, taking the protein degradation drug developer's total funding to more than $95m.